1 Disease Elimination Program, Burnet Institute, Melbourne, Australia. firstname.lastname@example.org.
2 Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Australia. email@example.com.
3 Disease Elimination Program, Burnet Institute, Melbourne, Australia.
4 Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Australia.
5 Department of Medicine, The University of Melbourne, Parkville, Australia.
6 Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Australia.
7 Nuffield Department of Medicine, University of Oxford, Oxford, UK.
8 NIHR Oxford Biomedical Research Centre, Oxford University NHS Trust, Oxford, UK.
9 Department of Paediatrics, Ain Shams University, Cairo, Egypt.
10 Global Medical Director for Aids Health Care Foundation, Brasília, DF, Brazil.
11 Department of Microbiology, Monash University, Clayton, Australia.
12 Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Australia.
13 Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia.
The introduction of highly effective direct-acting antiviral (DAA) therapy for hepatitis C has led to calls to eliminate it as a public health threat through treatment-as-prevention. Recent studies suggest it is possible to develop a vaccine to prevent hepatitis C. Using a mathematical model, we examined the potential impact of a hepatitis C vaccine on the feasibility and cost of achieving the global WHO elimination target of an 80% reduction in incidence by 2030 in the era of DAA treatment.
The model was calibrated to 167 countries and included two population groups (people who inject drugs (PWID) and the general community), features of the care cascade, and the coverage of health systems to deliver services. Projections were made for 2018-2030.
The optimal incidence reduction strategy was to implement test and treat programmes among PWID, and in settings with high levels of community transmission undertake screening and treatment of the general population. With a vaccine available, the optimal strategy was to include vaccination within test and treat programmes, in addition to vaccinating adolescents in settings with high levels of community transmission. Of the 167 countries modelled, between 0 and 48 could achieve an 80% reduction in incidence without a vaccine. This increased to 15-113 countries if a 75% efficacious vaccine with a 10-year duration of protection were available. If a vaccination course cost US$200, vaccine use reduced the cost of elimination for 66 countries (40%) by an aggregate of US$7.4 (US$6.6-8.2) billion. For a US$50 per course vaccine, this increased to a US$9.8 (US$8.7-10.8) billion cost reduction across 78 countries (47%).
These findings strongly support the case for hepatitis C vaccine development as an urgent public health need, to ensure hepatitis C elimination is achievable and at substantially reduced costs for a majority of countries.